Management of Facial Cellulitis
First-Line Oral Antibiotic Therapy
For typical non-purulent facial cellulitis without MRSA risk factors, initiate a β-lactam antibiotic such as cephalexin 500 mg four times daily, dicloxacillin 500 mg four times daily, or amoxicillin for 5 days. 1, 2
- β-hemolytic streptococci (particularly S. pyogenes) and methicillin-susceptible Staphylococcus aureus are the predominant pathogens in typical facial cellulitis, making β-lactam antibiotics the appropriate empiric choice. 1, 3
- A prospective study demonstrated 96% clinical success with β-lactam therapy (cefazolin or oxacillin) for non-purulent cellulitis, confirming that routine MRSA coverage is unnecessary in typical cases. 1
- A 5-day antibiotic course is as effective as 10 days if clinical improvement occurs by day 5; extending therapy beyond this provides no additional benefit. 4, 1, 5
Alternative Oral Agents for β-Lactam Allergy
- Clindamycin 300–450 mg three times daily provides coverage for both streptococci and MSSA. 6, 1
- Macrolides (e.g., azithromycin) may be considered, though 8–9% of S. pyogenes strains show macrolide resistance in the United States. 6
When to Add MRSA-Active Coverage
Add empiric MRSA coverage if any of the following high-risk features are present:
- Lack of clinical response after 48–72 hours of β-lactam therapy. 1, 2
- Purulent drainage or exudate (purulent cellulitis phenotype). 7, 1, 2
- Penetrating trauma (especially injection drug use) or documented MRSA colonization. 7, 1, 2
- Systemic toxicity: fever, hypotension, altered mental status, or meeting SIRS criteria (≥2 of: temperature >38°C or <36°C, heart rate >90 bpm, respiratory rate >20/min, WBC >12,000 or <4,000 cells/mm³). 7, 1, 2
Oral MRSA-Active Regimens
| Agent | Dose | Coverage Notes |
|---|---|---|
| Clindamycin | 300–450 mg PO three times daily | Covers both MRSA and streptococci [7,1] |
| TMP-SMX | 1–2 double-strength tablets PO twice daily | MRSA only; must add a β-lactam (amoxicillin or cephalexin) for streptococcal coverage [7,1,2] |
| Doxycycline | 100 mg PO twice daily | MRSA only; must add a β-lactam for streptococcal coverage [7,1,2] |
| Linezolid | 600 mg PO twice daily | Covers MRSA and streptococci; more expensive [7,1] |
- Critical pitfall: TMP-SMX and doxycycline lack reliable activity against β-hemolytic streptococci and should never be used as monotherapy for non-purulent cellulitis. 7, 1, 2
- The clinical significance of inducible clindamycin resistance in mild infections is unclear, but its presence should preclude clindamycin use in severe infections. 7
Criteria for Intravenous Therapy
Initiate IV antibiotics for patients meeting any of the following criteria:
- Severe or rapidly progressive disease involving multiple sites or with associated systemic illness (fever, tachycardia, hypotension, altered mental status). 7
- Inability to tolerate oral medications or concern for absorption. 1
- Immunosuppression or significant comorbidities (diabetes, HIV/AIDS, malignancy). 7
- Facial location with difficult drainage (e.g., periorbital involvement, concern for deep-space infection). 7, 2
- Lack of response to appropriate oral antibiotics after 48–72 hours. 1, 2
- Extremes of age (very young or elderly with frailty). 7
Recommended IV Regimens (7–14 days)
| Agent | Dose | Comment |
|---|---|---|
| Vancomycin | 15–20 mg/kg IV every 8–12 hours | First-line MRSA-active agent [7,1,2] |
| Cefazolin | 1–2 g IV every 8 hours | For non-purulent cellulitis; switch to MRSA coverage if no response [1,2] |
| Linezolid | 600 mg IV/PO twice daily | Alternative MRSA agent [7,1,2] |
| Daptomycin | 4 mg/kg IV once daily | MRSA-active option [7,1,2] |
| Clindamycin | 600 mg IV three times daily | Use only if local clindamycin resistance <10% [7,1] |
- A retrospective study found no difference in clinical outcomes between IV and oral antibiotics for cellulitis of similar severity, suggesting that oral therapy is appropriate for most patients who can tolerate it. 5
- Transition to oral therapy once clinical improvement is evident (reduced erythema, swelling, tenderness) and the patient is afebrile for 24 hours. 1
Special Considerations for Facial Cellulitis
- Periorbital/orbital involvement: Obtain urgent ophthalmology consultation if there is proptosis, vision changes, ophthalmoplegia, or severe periorbital swelling to rule out orbital cellulitis or abscess. 8
- Dental source: Consider odontogenic infection if cellulitis involves the lower face or jaw; may require dental evaluation and drainage. 1
- Surgical consultation: Obtain if there is concern for necrotizing fasciitis (rapidly progressive, severe pain out of proportion to exam, skin necrosis, crepitus), deep-space infection, or abscess requiring drainage. 1, 2
Monitoring and Reassessment
- Reassess at 48–72 hours after initiating therapy to confirm clinical improvement (reduction in erythema, swelling, tenderness, and systemic symptoms). 6, 1, 2
- Mark the border of erythema with a pen at initial evaluation to objectively track progression or improvement. 1
- If worsening or no improvement by 48–72 hours, consider:
Common Pitfalls to Avoid
- Do not routinely obtain blood cultures or imaging for typical outpatient cellulitis; reserve these for patients with severe systemic features, immunosuppression, or atypical exposures. 1, 2
- Do not add rifampin as adjunctive therapy; it provides no clinical benefit and promotes antimicrobial resistance. 1, 2
- Do not extend antibiotics beyond 5 days in patients who are clinically improving; this constitutes overtreatment without added benefit. 4, 1, 5
- Do not use TMP-SMX or doxycycline alone for non-purulent cellulitis; always combine with a β-lactam if MRSA coverage is needed. 7, 1, 2
- Avoid clindamycin for serious infections if inducible resistance is detected, as treatment failure may occur. 7